Brief: Pds Biotech Announces Submission Of Phase 3 Protocol To FDA To Initiate Versatile-003 Trial

PDS Biotechnology

14/08/2023 12:08

PDS Biotechnology Corp  PDSB.O :
    * PDS BIOTECH ANNOUNCES SUBMISSION OF PHASE 3 PROTOCOL TO
FDA TO
INITIATE VERSATILE-003 TRIAL
    * PDS BIOTECHNOLOGY CORP - ANTICIPATES INITIATING
VERSATILE-003
TRIAL IN Q4 OF 2023
    * PDS BIOTECHNOLOGY - VERSATILE-003 WILL EVALUATE PDS0101 IN
COMBINATION WITH KEYTRUDA(®) IN RECURRENT OR METASTATIC
HPV16-POSITIVE HEAD AND NECK CANCER
    * PDS BIOTECHNOLOGY CORP - PHASE 3 STUDY IS EXPECTED TO
INVOLVE
APPROXIMATELY 90-100 CLINICAL SITES GLOBALLY
    * PDS BIOTECHNOLOGY CORP: PDS BIOTECH ANTICIPATES INITIATING
VERSATILE-003 PHASE 3 TRIAL IN Q4 OF 202
    * PDS BIOTECHNOLOGY CORP: PHASE 3 STUDY IS EXPECTED TO
INVOLVE
APPROXIMATELY 90-100 CLINICAL SITES GLOBALLY

Source text for Eikon:  ID:nGNX9BDSgB 
Further company coverage:  PDSB.O